Follow-The-Filings

Security · featured owners

TVTX Travere Therapeutics Inc.

Health Care COM Equity as of 2026 Q2 among managers we track

  • 2 Owners
  • Max 1.3%
  • $11M
  • 1 new 1 reduce 1 exit

TVTX (Travere Therapeutics Inc.) is held in 2 featured 13F books as of 2026 Q2. Palo Alto Investors is the largest tracked holder by portfolio weight (1.3%). Figures are as-filed 13F, not free float.

Who owns this now

Largest portfolio weights among featured holders · max 1.3% (Palo Alto Investors) · not free-float ownership

  1. Palo Alto Investors Reduce 1.3%
  2. Polen Capital Management New 0.02%

Holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

History
Palo Alto Investors 2026 Q2 1.3% Reduce −27.3% 167,525 $10M History
Polen Capital Management 2026 Q2 0.02% New 0.02% 34,315 $2M History
Farallon Capital Management exited 2026 Q2 Last 2026 Q1 <0.01% Exit 0.00% 12,000 $357K History

2 current · 1 exited last period · options excluded

SEC filings

Recent issuer filings from EDGAR · 9 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 5.02,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02 Filing Doc
8-K 5.02 Filing Doc
8-K 1.01,9.01 Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
8-K 1.01,2.03,3.02,8.01,9.01 Filing Doc
424B5 Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 9 rows shown

Filed Form Detail Links
4 Period Sep 15, 2026 · 7 forms Filing Doc
4 Period Sep 10, 2026 Filing Doc
4 Period Sep 2, 2026 Filing Doc
4 Period Aug 17, 2026 Filing Doc
4 Period Jun 22, 2026 Filing Doc
4 Period Jun 12, 2026 · 2 forms Filing Doc
4 Period May 19, 2026 · 9 forms Filing Doc
4 Period May 15, 2026 Filing Doc
4 Period May 4, 2026 · 2 forms Filing Doc

Updated 8 days ago Source: SEC EDGAR submissions All on EDGAR

Financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $145.24M $233.18M $490.73M
Gross profit * $133.79M $225.43M $480.39M
Gross margin * 92.1% 96.7% 97.9%
Net income -$111.4M -$321.54M -$25.55M
Net margin * -76.7% -137.9% -5.2%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $616.78M $416.7M $437.56M
Total non-current assets * $172.14M $177.42M $167.63M
Total assets $788.91M $594.12M $605.19M
Total current liabilities $177.91M $200.75M $159.9M
Total non-current liabilities * $410.2M $334.3M $330.46M
Total equity $200.81M $59.08M $114.83M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$280.02M -$237.48M $37.78M
Cash from investing $55.78M $99.32M $27.89M
Cash from financing $218.75M $139.42M -$33.47M
Net change in cash -$3.51M $0.359M $34.5M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

Ownership over time

filing count by report period · click a bar for that quarter’s holders